Pemphigus vulgaris (PV) is a rare autoimmune mucocutaneous blistering disease associated with significant morbidity when not treated promptly. While most patients are initially treated with glucocorticoids and adjuvant immunosuppressive agents by a dermatologist, some patients are nonresponsive. This interactive web monograph provides an overview of PV and its diagnosis and current treatment as well as data on the safety and efficacy of emerging therapies such as rituximab, dapsone, and methotrexate. Because most dermatologists do not provide infusion therapies, they often confer with rheumatologists, who are better equipped to screen patients for suitability for intravenous infusion of biologics such as rituximab. Rheumatologists therefore need to be aware of their potential role in managing these patients in concert with dermatologists.
Ratings and Reviews
To review this course, please login.Login